As of Nov 19, 2026, 1 of 1 active firms rate SURG a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
SURG EPS & revenue forecast
EPS · NEXT QUARTER
$-0.05
Range $-0.05 – $-0.05 · 1 analysts · -93% YoY
Next period, 1 analysts expect Surgepays Inc to earn $-0.05 a share (range $-0.05 – $-0.05), versus $-0.69 a year earlier. Full-year consensus is $-0.44, growing to $0.01 the year after.
REVENUE · NEXT QUARTER
$16.2M
Range $16.2M – $16.2M · 1 analysts · +0% YoY
Revenue is expected to reach $16.2M (range $16.2M – $16.2M), +0.1% year-over-year. Full-year consensus is $64.9M, rising to $70.1M next year.
Top analysts covering Surgepays Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SURG.
#1
MD
Michael Diana
Maxim Group · Rank #224
Neutral
No targeton SURG
Overall win rate
42%
+ Follow
#2
Edward Woo
Ascendiant Capital · Rank #570
Buy
$3.75+2613.5% to target
Overall win rate
24%
+ Follow
#3
EW
Edward Woo
Ascendiant
Buy
$3.50+2432.6% to target
Coverage
—
+ Follow
SURG stock forecast FAQ
What is SURG's average 12-month price target?+
The 1 active firms with a live target average $3.75 for Surgepays Inc over the next 12 months, ranging from a $3.75 high to a $3.75 low, as of Nov 19, 2026.
Is SURG stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover SURG?+
1 active firms have a recognized rating on Surgepays Inc as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering SURG?+
Among analysts who currently cover SURG, Michael Diana of Maxim Group has the strongest overall Quantellect track record (Rank #224). Their current call is Neutral.
What is Surgepays Inc's projected EPS for next quarter?+
The consensus estimate is $-0.05 per share (range $-0.05 – $-0.05) across 1 analysts. Full-year EPS is projected at $-0.44, rising to $0.01 the following year.
How much revenue is Surgepays Inc expected to report next quarter?+
Consensus revenue is $16.2M (range $16.2M – $16.2M). Full-year revenue is projected at $64.9M, growing to $70.1M next year.
Have analysts been upgrading or downgrading SURG lately?+
As of Nov 19, 2026, 1 of 1 active firms rate SURG a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SURG calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.